Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Kintor Starts China Trial of Combination Therapy for Liver Cancer

publication date: Oct 13, 2021

Suzhou Kintor Pharma was approved to start a China Phase I trial of its ALK-1 antibody in combination with Bristol-Myers Squibb's PD-1, nivolumab (Opdivo®), in patients with advanced hepatocellular carcinoma. The ALK-1 antibody is a fully human IgG2 neutralizing mAb that inhibits ALK-1/TGF-β signal transduction, interrupting tumor angiogenesis and changing the tumor microenvironment. In 2018, Kintor acquired an exclusive global license from Pfizer for the candidate in all oncological applications. More details....

Stock Symbol: (HK: 9939)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.